In-Process Research and Development, Net (Details) - LYMPHIR [Member] - USD ($) |
3 Months Ended | 6 Months Ended | ||
|---|---|---|---|---|
Mar. 31, 2026 |
Mar. 31, 2025 |
Mar. 31, 2026 |
Mar. 31, 2025 |
|
| In-Process Research and Development, Net [Line Items] | ||||
| In process research and development gross | $ 73,400,000 | $ 73,400,000 | ||
| In process research and development net | 71,106,250 | 71,106,250 | ||
| Amortization of research and development process | $ 1,720,312 | $ 0 | $ 2,293,750 | $ 0 |
| X | ||||||||||
- Definition Amount of amortization of in-process research and development. No definition available.
|
| X | ||||||||||
- Definition Amount, before accumulated amortization, of finite-lived intangible asset. Excludes goodwill and capitalized cost for software to be sold, leased, or marketed. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Amount, after accumulated amortization, of finite-lived intangible asset. Excludes goodwill and capitalized cost for software to be sold, leased, or marketed. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Details
|